Medical Research Future Fund: Cardiovascular Health Mission Implementation Plan

Objectives

The Cardiovascular Health Mission is a 10-year Medical Research Future Fund investment of 220 million Australian dollars to reduce the number of Australians affected by heart disease and stroke, improve outcomes across prevention, acute care, recovery and survivorship, and translate research into health-system benefit.[1][2]It places equity at the centre of its agenda, particularly for Aboriginal and/or Torres Strait Islander people, through culturally secure research, care and leadership approaches.[1][3][4]

• Improve understanding of cardiovascular disease risk, including biological mechanisms, risk prediction, early detection, care inequities and implementation approaches.[2]
• Strengthen prevention through best-practice and tailored care, culturally secure interventions, adherence support, clinical pathways, novel therapeutics and technologies, and action on inequalities.[1][5]
• Optimise acute cardiovascular and stroke outcomes through evidence-based diagnosis, prognosis, management of time-dependent events, clinical pathways, technologies, medicines, devices and models of care.[1][6][7]
• Advance discovery and innovation by developing, adopting and validating new treatments, biomarkers, devices and care models over short-, medium- and long-term timeframes.[7]
• Improve recovery and survivorship through personalised lifelong care, rehabilitation, monitoring, treatment adherence and interventions that prevent recurrent heart events or strokes and reduce morbidity.[1][4][8]
• Support diabetes and cardiovascular research through the Targeted Translation Research Accelerator, including research on shared disease pathways, prevention, diagnosis and treatment.[9][2]

Implementation

The mission uses nationally coordinated, competitive and translational research investment to build knowledge and capability, support discovery and implementation, and embed effective innovations in clinical practice and the health system.[1][9]Delivery combines co-design, clinical trials, implementation and systems research, linked data infrastructure, workforce development, partnerships and commercialisation to move promising diagnostics, therapeutics, devices and care pathways into use.[2][5][10]

• Co-design research and services with consumers and end users, including Aboriginal and/or Torres Strait Islander people in research leadership and culturally secure approaches to prevention, acute care, rehabilitation and recovery.[1][9][6][8]
• Coordinate funded activity nationally to avoid duplication, align projects, connect research alliances and cardiovascular platforms, and link research with quality improvement and health-service delivery.[9][10][8]
• Develop large-scale data, biobank and registry platforms that integrate clinical, population, primary-care and routinely collected health data to support research, clinical decision-making, near real-time monitoring and quality assurance.[5][3][6]
• Embed clinical trials in primary care, health-research and health-translation networks, including registry-based and virtual approaches, while strengthening clinical, data-analysis, data-management and research-career capability.[3][6][7]
• Engage governments, health services, researchers, professional bodies, consumers, communities, universities, foundations, insurers, industry, biotechnology and medical-technology companies, and international partners.[9][3][7][4]
• Accelerate translation through the Targeted Translation Research Accelerator, a 47 million Australian dollar programme over four years that supports competitive research centres, grants, partnership projects, early-stage therapeutic investment and health and commercial-sector transformation.[9][2]
• Support implementation through software and digital-health development, artificial intelligence and data analytics, tele-rehabilitation, consumer engagement, performance dashboards, policy engagement, intellectual-property capability and commercialisation business cases.[3][4][10][8]
• Mobilise additional resources through co-funded grants, collaboration with other Medical Research Future Fund missions, potential matched funding from the Heart Foundation and Stroke Foundation, commercial partnerships, venture capital, philanthropy, insurer partnerships and international collaboration.[2][6][10][8]
• Evaluate grants, initiatives and the overall programme under the Medical Research Future Fund Monitoring, Evaluation and Learning Strategy, using independent, transparent evaluations; review the mission and funded grants after three years of disbursements and adjust investment priorities if warranted.[9]
• Track national availability and clinical uptake of discoveries, biomarkers, pathways, treatments and rehabilitation; access to risk assessment, preventive and acute care; inequality reductions; research translation; and health, economic and social value.[3][7][4][8][11]

Monitoring & Evaluation

Monitoring and evaluation are framed by the Medical Research Future Fund Monitoring, Evaluation and Learning Strategy, covering individual grants, grant opportunities, initiatives and the programme as a whole.[9]Evaluation is intended to be independent, impartial and transparent, while responding to the needs of the fund, consumers, stakeholders and the health and medical research sector.[9]The Cardiovascular Health Mission and funded grants are to be evaluated after three years of disbursements, with findings informing possible revision of investment priorities or identification of new priorities.[9]

• Assess patient benefits within each priority area to track progress towards the mission’s objectives.[1]
• Measure the national availability and clinical use of new cardiovascular disease and stroke biomarkers, discoveries, clinical pathways, optimised treatments, and novel interventions, devices and technologies.[3][7]
• Monitor whether more eligible people receive cardiovascular and stroke risk assessments, whether people at risk receive best-practice preventive care, and whether individual and community prevention approaches are implemented nationally.[3]
• Track the proportion of people with cardiovascular disease or stroke who receive best-practice acute care and effective rehabilitation, including equitable access for populations at risk and reductions in inequalities affecting Aboriginal and/or Torres Strait Islander people.[4][8][11]
• Use clinical-quality registries, linked routine health, primary-care and electronic health-record data, virtual registries and performance dashboards to enable near real-time monitoring, quality assurance, clinical decision support and assessment of care and outcomes.[3][6]
• Apply health, economic and social value measures, including economic evaluations, impact assessments, health-economic implications and potential return on investment, to assess prevention pathways, innovations and research translation.[5][3][7]
• Use health-system monitoring, consumer feedback, policy change, registry-based clinical trials and consumer-relationship management platforms to support continuing assessment and implementation.[7][4]
• Evaluate whether research is translated into practice and incorporated into acute-care guidelines or policy.[6]

Beyond the three-year evaluation point and the specified outcome measures, the supplied material does not set out quantitative targets, a detailed reporting timetable, surveillance protocols or named accountability bodies.[9][2][5][11]

Costing & Financing

The Cardiovascular Health Mission has an investment envelope of $220 million over 10 years through the Medical Research Future Fund.[1]A major enabling investment is the Targeted Translation Research Accelerator, funded at $47 million over four years for research on prevention, diagnosis and treatment of diabetes and cardiovascular disease.[9][2]

• Support research centres, competitive grants, partnership projects, early-stage therapeutic investment, and research intended to transform health and commercial sectors through the Targeted Translation Research Accelerator.[2]
• Mobilise additional resources through co-funded grants, collaboration across Medical Research Future Fund missions, commercial partnerships, private health-insurer partnerships, international collaboration, philanthropic support, venture capital and co-investment opportunities.[2][5][10][8]
• Explore potential matched funding with the Heart Foundation and Stroke Foundation, where feasible, to promote implementation and evaluation.[6]
• Develop commercialisation business cases and engage biotechnology, pharmaceutical, medical-technology and global industry partners to support innovation, clinical-trial networks, research infrastructure and translation.[7][4]
• Consider health-economic assessment, research impact and potential return on investment when evaluating preventive pathways, treatments and service innovations.[5][3]

The material does not specify annual budgets, allocations by priority area or activity, expenditure profiles, funding-gap estimates, financing targets, or detailed economic assumptions beyond the stated investments and proposed health-economic assessment activity.[1][2][3][7][8]